Assessing the Efficacy of Latanoprost vs Timolol Using an Alternate Efficacy Parameter: The Intervisit Intraocular Pressure Range

American Journal of Ophthalmology

Volumn 148, Issue 2, 2009, Pages 221-226

  Varma, Rohit ^a   Hwang, Lie Ju ^b   Grunden, John W ^b   Bean, Gerald W ^c   Sultan, Marla B ^b,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c Burkett   (United States)

^d NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; TIMOLOL;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EVENING DOSAGE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; MORNING DOSAGE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; OPEN ANGLE GLAUCOMA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 67650432141     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.02.035     Document Type: Article

References (30)

1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126 (1998) 498-505
3. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120 (2002) 1268-1279
4. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 121 (2003) 48-56
5. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
6. Bergeå B., Bodin L., and Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 106 (1999) 997-1004
7. Caprioli J., and Coleman A.L. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology 115 (2008) 1123-1129
8. Hong S., Seong G.J., and Hong Y.J. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch Ophthalmol 125 (2007) 1010-1013
9. O'Brien C., Schwartz B., Takamoto T., and Wu D.C. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 111 (1991) 491-500
10. Stewart W.C., Kolker A.E., Sharpe E.D., et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 130 (2000) 274-279
11. Orzalesi N., Fogagnolo P., and Rossetti L. Intraocular pressure fluctuations in glaucoma. Arch Ophthalmol 126 (2008) 745
12. Weinreb R.N., and Liu J.H. Nocturnal rhythms of intraocular pressure. Arch Ophthalmol 124 (2006) 269-270
13. Varma R., Hwang L.J., Grunden J.W., and Bean G.W. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmol 145 (2008) 336-342
14. Parrish R.K., Palmberg P., Sheu W.P., and XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 (2003) 688-703
15. Camras C.B., and United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a 6-month masked, multicenter trial in the United States. Ophthalmology 103 (1996) 138-147
16. Watson P., Stjernschantz J., and Latanoprost Study Group. A 6-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103 (1996) 126-137
17. Alm A., Stjernschantz J., and Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 102 (1995) 1743-1752
18. Hedman K., and Alm A. A pooled-data analysis of three randomized, double-masked, 6-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 10 (2000) 95-104
19. Bengtsson B., and Heijl A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension. Graefes Arch Clin Exp Ophthalmol 243 (2005) 513-518
20. Saccá S.C., Rolando M., Marletta A., et al. Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma, and normal subjects. Ophthalmologica 212 (1998) 115-119
21. Bengtsson B., Leske M.C., Hyman L., and Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology 114 (2007) 205-209
22. Forsman E., Kivelä T., and Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma 16 (2007) 313-319
23. Nouri-Mahdavi K., Hoffman D., Coleman A.L., et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111 (2004) 1627-1635
24. Simmons S.T., Bernstein P., and Hollander D.A. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Am J Ophthalmol 146 (2008) 473-477
25. Javitt J.C., McBean A.M., Nicholson G.A., Babish J.D., Warren J.L., and Krakauer H. Undertreatment of glaucoma among Black Americans. N Engl J Med 325 (1991) 1418-1422
26. Sommer A., Tielsch J.M., Katz J., et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 325 (1991) 1412-1417
27. Friedman D.S., Wilson M.R., Liebmann J.M., et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 138 (2004) S19-S31
28. Higginbotham E.J., Gordon M.O., Beiser J.A., et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 122 (2004) 813-820
29. Tielsch J.M., Sommer A., Katz J., et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 266 (1991) 369-374
30. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology 105 (1998) 1137-1145